Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
News) - GW Pharmaceuticals PLC Monday said it was focused on the approval of its flagship drug Epidiolex in childhood- ...
- Three Positive Phase 3 Epidiolex clinical trials reported in 2016 -- NDA submission and launch preparation on track -- Conference call today at 8:00 a.m. EST - LONDON, Dec. 05, 2016...
AIM 05 December 2016 NOTICE 05/12/2016 7:00am NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM GW PHARMACEUTICALS PLC At the request of the company trading on AIM for the under-mentioned...
GW Pharmaceuticals PLC 01 December 2016 GW Pharmaceuticals plc Announces Epidiolex(R) (cannabidiol) Data Presentations and Educational Programs at the American Society of Epilepsy Annual Meeting...
- Presentations include clinical results from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet Syndrome, as well as additional independent reports from Epidiolex Expanded Access...
GW Pharmaceuticals PLC 30 November 2016 GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 5 December, 2016 London, UK, 30 Nov 2016: GW Pharmaceuticals plc...
LONDON, Nov. 30, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and...
GW Pharmaceuticals PLC 24 November 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or GW Pharmaceuticals PLC the underlying issuer of existing shares to which...
LONDON, Nov. 22, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
